Publication: Inhibition of bacterial disulfide bond formation by the anticoagulant warfarin
No Thumbnail Available
Open/View Files
Date
2010
Published Version
Journal Title
Journal ISSN
Volume Title
Publisher
National Academy of Sciences
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
Dutton, R. J., A. Wayman, J.-R. Wei, E. J. Rubin, J. Beckwith, and D. Boyd. 2009. “Inhibition of Bacterial Disulfide Bond Formation by the Anticoagulant Warfarin.” Proceedings of the National Academy of Sciences 107 (1): 297–301. https://doi.org/10.1073/pnas.0912952107.
Research Data
Abstract
Blood coagulation in humans requires the activity of vitamin K epoxide reductase (VKOR), the target of the anticoagulant warfarin (Coumadin). Bacterial homologs of VKOR were recently found to participate in a pathway leading to disulfide bond formation in secreted proteins of many bacteria. Here we show that the VKOR homolog from the bacterium Mycobacterium tuberculosis, the causative agent of human tuberculosis, is inhibited by warfarin and that warfarin-resistant mutations of mycobacterial VKOR appear in similar locations to mutations found in human patients who require higher doses of warfarin. Deletion of VKOR results in a severe growth defect in mycobacteria, and the growth of M. tuberculosis is inhibited by warfarin. The bacterial VKOR homolog may represent a target for antibiotics and a model for genetic studies of human VKOR. We present a simple assay in Escherichia coli, based on a disulfide-sensitive beta-galactosidase, which can be used to screen for stronger inhibitors of the M. tuberculosis VKOR homolog.
Description
Other Available Sources
Keywords
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service